VitaNova Life Sciences Corporation (VNOV)
OTCMKTS · Delayed Price · Currency is USD
2.380
0.00 (0.00%)
Oct 8, 2026, 4:00 PM EDT
VitaNova Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
Cash & Equivalents | 1.6 | 1.6 | 0.78 | 0.59 | 0.01 | 0.02 |
Cash & Short-Term Investments | 1.6 | 1.6 | 0.78 | 0.59 | 0.01 | 0.02 |
Cash Growth | 53.27% | 104.04% | 32.00% | 6694.64% | -62.22% | - |
Receivables | 0.32 | 0.73 | 1.27 | - | - | - |
Inventory | 0.3 | 0.11 | 0.04 | 0.13 | - | - |
Other Current Assets | 0 | 0 | 0.16 | 0.47 | - | - |
Total Current Assets | 2.22 | 2.43 | 2.26 | 1.19 | 0.01 | 0.02 |
Long-Term Deferred Tax Assets | 0.02 | 0.02 | - | - | - | - |
Total Assets | 2.24 | 2.45 | 2.26 | 1.19 | 0.01 | 0.02 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
Accounts Payable | 0.12 | 0.21 | - | 0.06 | 0.05 | - |
Accrued Expenses | 0.08 | 0.08 | 0.06 | - | - | 0.05 |
Short-Term Debt | - | - | - | 0 | 0.02 | 0.01 |
Current Income Taxes Payable | 0.11 | 0.11 | 0.29 | 0.06 | - | - |
Other Current Liabilities | - | - | - | 0.01 | - | - |
Total Current Liabilities | 0.31 | 0.4 | 0.35 | 0.14 | 0.07 | 0.06 |
Total Liabilities | 0.31 | 0.4 | 0.35 | 0.14 | 0.07 | 0.06 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 | 0.01 |
Additional Paid-In Capital | 1.03 | 1.03 | 1.03 | 1.01 | 0.06 | 0.06 |
Retained Earnings | 0.71 | 0.83 | 0.87 | 0.02 | -0.12 | -0.1 |
Comprehensive Income & Other | 0.18 | 0.18 | 0 | 0 | - | - |
Shareholders' Equity | 1.93 | 2.05 | 1.91 | 1.06 | -0.06 | -0.03 |
Total Liabilities & Equity | 2.24 | 2.45 | 2.26 | 1.19 | 0.01 | 0.02 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
Total Debt | - | - | - | 0 | 0.02 | 0.01 |
Net Cash (Debt) | 1.6 | 1.6 | 0.78 | 0.59 | -0.01 | 0.01 |
Net Cash Growth | 53.27% | 104.04% | 32.67% | - | - | - |
Net Cash Per Share | 0.19 | 0.19 | 0.09 | 0.17 | -0.00 | 0.01 |
Filing Date Shares Outstanding | 8.34 | 8.34 | 8.34 | 8.34 | 1.96 | 1.96 |
Total Common Shares Outstanding | 8.34 | 8.34 | 8.34 | 8.34 | 1.96 | 1.96 |
Working Capital | 1.91 | 2.03 | 1.91 | 1.06 | -0.06 | -0.03 |
Book Value Per Share | 0.23 | 0.25 | 0.23 | 0.13 | -0.03 | -0.02 |
Tangible Book Value | 1.93 | 2.05 | 1.91 | 1.06 | -0.06 | -0.03 |
Tangible Book Value Per Share | 0.23 | 0.25 | 0.23 | 0.13 | -0.03 | -0.02 |